Harmonized procedures lead to comparable quantification of total oxylipins across laboratories

Oxylipins are potent lipid mediators involved in a variety of physiological processes. Their profiling has the potential to provide a wealth of information regarding human health and disease and is a promising technology for translation into clinical applications. However, results generated by independent groups are rarely comparable, which increases the need for the implementation of internationally agreed upon protocols. We performed an interlaboratory comparison for the MS-based quantitative analysis of total oxylipins. Five independent laboratories assessed the technical variability and comparability of 133 oxylipins using a harmonized and standardized protocol, common biological materials (i.e., seven quality control plasmas), standard calibration series, and analytical methods. The quantitative analysis was based on a standard calibration series with isotopically labeled internal standards. Using the standardized protocol, the technical variance was within ±15% for 73% of oxylipins; however, most epoxy fatty acids were identified as critical analytes due to high variabilities in concentrations. The comparability of concentrations determined by the laboratories was examined using consensus value estimates and unsupervised/supervised multivariate analysis (i.e., principal component analysis and partial least squares discriminant analysis). Interlaboratory variability was limited and did not interfere with our ability to distinguish the different plasmas. Moreover, all laboratories were able to identify similar differences between plasmas. In summary, we show that by using a standardized protocol for sample preparation, low technical variability can be achieved. Harmonization of all oxylipin extraction and analysis steps led to reliable, reproducible, and comparable oxylipin concentrations in independent laboratories, allowing the generation of biologically meaningful oxylipin patterns.

[1]  I. Bechmann,et al.  Tissue pretreatment for LC–MS/MS analysis of PUFA and eicosanoid distribution in mouse brain and liver , 2019, Analytical and Bioanalytical Chemistry.

[2]  J. Bertrand-Michel,et al.  Stability of oxylipins during plasma generation and long-term storage. , 2020, Talanta.

[3]  J. Clària,et al.  Role of bioactive lipid mediators in obese adipose tissue inflammation and endocrine dysfunction , 2016, Molecular and Cellular Endocrinology.

[4]  P. Kris-Etherton,et al.  Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation , 2018, Scientific Reports.

[5]  Mats O. Karlsson,et al.  Handling Data Below the Limit of Quantification in Mixed Effect Models , 2009, The AAPS Journal.

[6]  J. Galano,et al.  Development of an LC-ESI(-)-MS/MS method for the simultaneous quantification of 35 isoprostanes and isofurans derived from the major n3- and n6-PUFAs. , 2017, Analytica chimica acta.

[7]  A. I. Ostermann,et al.  Comparison of sample preparation methods for the quantitative analysis of eicosanoids and other oxylipins in plasma by means of LC-MS/MS , 2015, Analytical and Bioanalytical Chemistry.

[8]  J. Newman,et al.  Impact of circulating esterified eicosanoids and other oxylipins on endothelial function , 2009, Current atherosclerosis reports.

[9]  J. Mead Membrane lipid peroxidation and its prevention , 1980 .

[10]  Jonathan P. Benskin,et al.  Development, characterization and comparisons of targeted and non-targeted metabolomics methods , 2018, PloS one.

[11]  Jun Yang,et al.  Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. , 2009, Analytical chemistry.

[12]  Masanori Arita,et al.  MS-based lipidomics of human blood plasma: a community-initiated position paper to develop accepted guidelines1 , 2018, Journal of Lipid Research.

[13]  M. Holinstat,et al.  The emerging role of oxylipins in thrombosis and diabetes , 2014, Front. Pharmacol..

[14]  Jun Yang,et al.  Comparison of the effects of long-chain omega-3 fatty acid supplementation on plasma levels of free and esterified oxylipins. , 2014, Prostaglandins & other lipid mediators.

[15]  K. Weylandt,et al.  Modulation of the endogenous omega-3 fatty acid and oxylipin profile in vivo—A comparison of the fat-1 transgenic mouse with C57BL/6 wildtype mice on an omega-3 fatty acid enriched diet , 2017, PloS one.

[16]  P. Calder,et al.  Polyunsaturated fatty acids, inflammation, and immunity , 2001, Lipids.

[17]  Eoin Fahy,et al.  Lipidomics reveals a remarkable diversity of lipids in human plasma1[S] , 2010, Journal of Lipid Research.

[18]  CCQM Guidance note: Estimation of a consensus KCRV and associated Degrees of Equivalence , 2013 .

[19]  B. Hammock,et al.  Modulation of blood oxylipin levels by long-chain omega-3 fatty acid supplementation in hyper- and normolipidemic men. , 2014, Prostaglandins, leukotrienes, and essential fatty acids.

[20]  A. I. Ostermann,et al.  Effects of omega-3 fatty acid supplementation on the pattern of oxylipins: a short review about the modulation of hydroxy-, dihydroxy-, and epoxy-fatty acids. , 2017, Food & function.

[21]  Thomas Hankemeier,et al.  A Protective Lipidomic Biosignature Associated with a Balanced Omega-6/Omega-3 Ratio in fat-1 Transgenic Mice , 2014, PloS one.

[22]  E. Dennis,et al.  An integrated omics analysis of eicosanoid biology 1 , 2009 .

[23]  Mehdi Mirzaei,et al.  Inter-laboratory evaluation of instrument platforms and experimental workflows for quantitative accuracy and reproducibility assessment , 2015 .

[24]  W Greg Miller,et al.  Current practices and challenges in the standardization and harmonization of clinical laboratory tests. , 2016, The American journal of clinical nutrition.

[25]  A. I. Ostermann,et al.  A strategy for validating concentrations of oxylipin standards for external calibration. , 2019, Prostaglandins & other lipid mediators.

[26]  Matej Oresic,et al.  Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950–Metabolites in Frozen Human Plasma[S] , 2017, Journal of Lipid Research.

[27]  Xu Zhang,et al.  Systematic metabolomic analysis of eicosanoids after omega-3 polyunsaturated fatty acid supplementation by a highly specific liquid chromatography-tandem mass spectrometry-based method. , 2015, Journal of proteome research.

[28]  J. Mcgiff,et al.  20-HETE and the kidney: resolution of old problems and new beginnings. , 1999, The American journal of physiology.

[29]  J. Newman,et al.  MS-based targeted metabolomics of eicosanoids and other oxylipins: Analytical and inter-individual variabilities. , 2019, Free radical biology & medicine.

[30]  Markus R. Wenk,et al.  Shared reference materials harmonize lipidomics across MS-based detection platforms and laboratories[S] , 2019, Journal of Lipid Research.

[31]  C. Serhan,et al.  Lipid Mediator Metabolomics Via LC-MS/MS Profiling and Analysis. , 2018, Methods in molecular biology.

[32]  J. Newman,et al.  Lipid Profiling following Intake of the Omega 3 Fatty Acid DHA Identifies the Peroxidized Metabolites F4-Neuroprostanes as the Best Predictors of Atherosclerosis Prevention , 2014, PloS one.

[33]  Jerzy Adamski,et al.  Interlaboratory Reproducibility of a Targeted Metabolomics Platform for Analysis of Human Serum and Plasma. , 2017, Analytical chemistry.

[34]  J. Newman,et al.  Basal omega-3 fatty acid status affects fatty acid and oxylipin responses to high-dose n3-HUFA in healthy volunteers[S] , 2012, Journal of Lipid Research.

[35]  K. Weylandt,et al.  Analysis of omega-3 and omega-6 fatty acid-derived lipid metabolite formation in human and mouse blood samples. , 2011, Prostaglandins & other lipid mediators.

[36]  J. Galano,et al.  Development of an Optimized LC-MS Method for the Detection of Specialized Pro-Resolving Mediators in Biological Samples , 2019, Front. Pharmacol..

[37]  J. Mead,et al.  Autoxidation of fatty acid monolayers adsorbed on silica gel: II. Rates and products , 1977, Lipids.

[38]  A. Hahn,et al.  Effects of a 12-week high-α-linolenic acid intervention on EPA and DHA concentrations in red blood cells and plasma oxylipin pattern in subjects with a low EPA and DHA status. , 2018, Food & function.

[39]  A. I. Ostermann,et al.  Targeting Esterified Oxylipins by LC-MS - Effect of Sample Preparation on Oxylipin Pattern. , 2019, Prostaglandins & other lipid mediators.

[40]  M. Arita Mediator lipidomics in acute inflammation and resolution. , 2012, Journal of biochemistry.

[41]  U. Ceglarek,et al.  Fast liquid chromatography-quadrupole linear ion trap-mass spectrometry analysis of polyunsaturated fatty acids and eicosanoids in human plasma. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[42]  S. Rong,et al.  Characterization of changes in plasma and tissue oxylipin levels in LPS and CLP induced murine sepsis , 2015, Inflammation Research.

[43]  R. Gerszten,et al.  Targeted Metabolomics , 2012, Current protocols in molecular biology.

[44]  Mika,et al.  Modern Methods of Sample Preparation for the Analysis of Oxylipins in Biological Samples , 2019, Molecules.

[45]  John A. Bowden,et al.  Lipid Concentrations in Standard Reference Material (SRM) 1950: Results from an Interlaboratory Comparison Exercise for Lipidomics , 2017 .

[46]  E. Dennis,et al.  Quantitative determination of esterified eicosanoids and related oxygenated metabolites after base hydrolysis1[S] , 2018, Journal of Lipid Research.